Giant cell arteritis (GCA) is the most common form of vasculitis in the older adult population. There are variable clinical presentations of this entity and no perfect diagnostic test, often ...

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of AbbVie's upadacitinib (Rinvoq) to treat adults with giant cell arteritis (GCA).

Patients with predominantly cranial vs isolated extracranial GCA phenotypes present with different patterns of arterial involvement on 18F-FDG PET-CT scans.

Giant cell arteritis is a systemic vasculitis and careful attention should be given to the examination of the cardiovascular system including performing blood pressure measurements in both arms.

Giant cell arteritis, or GCA, is a condition where arteries in the head and neck become inflamed. It is called ‘giant cell’ because abnormally large cells accumulate in the artery walls.

EMA committee recommends approval of AbbVie’s upadacitinib to treat adults with giant cell arteritis: North Chicago, Illinois Monday, March 3, 2025, 15:00 Hrs [IST] AbbVie annou ...

"Giant cell arteritis is an inflammatory disease that, if left untreated, can lead to severe outcomes like blindness, stroke or aortic aneurysm,"2 said Prof. Dr. med. Wolfgang Schmidt, M.D., MACR ...

If approved, upadacitinib would be the first and only oral advanced therapy for adults living with giant cell arteritis. RINVOQ is approved in the European Union for the treatment of adults with ...

AbbVie said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended expanded approval of its blockbuster autoimmune drug Rinvoq for the treatment of adults ...